Phase I Dose Escalation Study of Taselisib (GDC-0032), an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors

Taselisib is a potent and selective tumor growth inhibitor through PI3K pathway suppression. Thirty-four patients with locally advanced or metastatic solid tumors were treated (phase I study, modified 3+3 dose escalation; 5 cohorts; 3-16 mg taselisib once daily capsule). Taselisib pharmacokinetics w...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Discov
Main Authors: Juric, Dejan, Krop, Ian, Ramanathan, Ramesh K., Wilson, Timothy R., Ware, Joseph A., Sanabria Bohorquez, Sandra M., Savage, Heidi M., Sampath, Deepak, Salphati, Laurent, Lin, Ray S., Jin, Huan, Parmar, Hema, Hsu, Jerry Y., Von Hoff, Daniel D., Baselga, Jose
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5501742/
https://ncbi.nlm.nih.gov/pubmed/28331003
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-16-1080
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados